Matthew K. Fust - 27 May 2026 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: Director
Issuer ticker: NMRA
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 16:30:38 UTC
Prior SEC filing: 18 May 2026
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Milligan, as Attorney-in-Fact for Matthew K. Fust

Key filing fact

Matthew K. Fust filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 29 May 2026.

Key facts

This page summarizes Matthew K. Fust's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001397266 Primary reporting owner

Fust Matthew K

Relationship: Director
Address: C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL PLACE, SUITE 1, WATERTOWN
Signature: /s/ Michael Milligan, as Attorney-in-Fact for Matthew K. Fust
Signature date: 29 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +80,000
Change %
Price: $0.000000^*
Shares after: 80,000
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $1.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.